![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA APPROVES NOVARTIS' VERSION OF TOPROL-XL
FDA APPROVES NOVARTIS' VERSION OF TOPROL-XL
August 4, 2006
Novartis, the world's second-largest generic drugmaker, won FDA approval for its version of AstraZeneca's Toprol-XL 25 mg hypertension drug.
AstraZeneca sold $1.7 billion worth of the drug in 2005, and the 25-mg dose represents about 20 percent of the drug's sales. Toprol-XL is AstraZeneca's third-best selling drug. The company is appealing a U.S. court loss over the patent.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct